Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

Condition:   Respiratory Syncytial Virus Infections Interventions:   Biological: RSVPreF3 OA Lot 1;   Biological: RSVPreF3 OA Lot 2;   Biological: RSVPreF3 OA Lot 3;   Biological: RSVPreF3 OA Lot 4;   Drug: Placebo Sponsor:   GlaxoSmithKline Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials